Search clinical trials for: EUS-FNB, PDL1, MMR

Total 617 results

Groupe Francais De Pneumo-Cancerologie

Completed

Epidemiologic Multicenter Prospective Study in Advanced NSCLC (Non Small Cell Lung Cancer) Patients With PDL1 (Protein Death Ligand 1) Expression. (EXPLORE-PDL1)

Lung Cancer

France
Second Affiliated Hospital of Guangzhou Medical...

Recruiting

Infusion of PD1/PDL1 Inhibitor Via Hepatic Arterial Versus Vein for Immunotherapy of Advanced Hepatocellular Carcinoma

Liver Cancer

China
Centre Hospitalier Universitaire de Besancon

Recruiting

Interest of Anti-telomerase T CD4 Immune Responses for Predicting the Effectiveness of Immunotherapies Targeting PD1 / PDL1 (ITHER)

Cancer

France
Chinese PLA General Hospital

Recruiting

CAPOX + Bevacizumab + Tirelizumab Treating PDL1 CPS < 5 GEA

Advanced Gastroesophageal Adenocarcinoma | First-line Therapy | PDL1 CPS < 5

China
Sohag University

Not yet recruiting

SOX2 & PDL1 Expression on Urinary Bladder Carcinoma

Urinary Bladder Neoplasm
Port Said University hospital
Mansoura University Hospital

Completed

PDL1 in Ovarian High Grade Serous Carcinoma

Ovarian Cancer

Egypt
Bristol-Myers Squibb

Completed

Multiple Ascending Dose (MDX1105-01) (Anti-PDL1)

Cancer, Multiple Indications

United States
Sorrento Therapeutics, Inc.

Withdrawn

Study of STI-3031 in Patients With Selected Relapsed or Refractory Solid Tumors

Solid Tumor | Relapsed Solid Tumor | Refractory Tumor
Ponderas Academic Hospital
University of Medicine and Pharmacy Craiova

Unknown

Evaluation of MMR Status and PD-L1 Expression Using Specimens Obtained by EUS-FNB in Patients With Pancreatic Cancer (SUCCESS)

Pancreatic Cancer
AstraZeneca

Completed

Asia PDL1 Study Among NSCLC Patients (MEDI-APEX)

Locally Advanced or Metastatic NSCLC

Korea, Republic of, China, Japan
The Affiliated Hospital of Qingdao University

Not yet recruiting

PD-L1 Inhibitor Rechallenge After PD-1 Immunotherapy for Patients With Solid Tumor Beyond Lung Cancer

Efficacy | Safety
Chinese PLA General Hospital
LinkDoc Technology (Beijing) Co. Ltd.

Unknown

A Real World Study of Anti-PD-1/PD-L1 Antibodies for the Treatment of Advanced Solid Tumors

Advanced Solid Tumors

China
University Hospital, Montpellier

Completed

Texture Features and PDL1 in CT-PET 18 FDG

Non Small Cell Lung Cancer

France
Sohag University

Not yet recruiting

PDL1 In Primary Colorectal Carcinoma and Its Prognostic Impact

PDL1- Colorectal Carcinoma
Eli Lilly and Company

Active, not recruiting

A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors (PACT)

Pancreatic Cancer | Solid Tumor | Cutaneous Melanoma | Microsatellite Instability-High (MSI-H) Solid Tumors | Breast Cancer (HR+HER2-)

France, Spain, Belgium, Korea, Republic of, United States, Taiwan, Canada
Adlai Nortye Biopharma Co., Ltd.

Active, not recruiting

The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC (BURAN)

Head and Neck Cancer

United States, United Kingdom, France, Hungary, Spain, Japan, Italy, Hong Kong, Taiwan, Korea, Republic of, Germany, Australia, China, Canada, Belgium, Argentina, Poland
Wuxi No. 4 People's Hospital

Unknown

89Zr-labeled KN035 PET Imaging in Patients With PD-L1 Positive Solid Tumors

Solid Tumor, Adult

China
Zhejiang Cancer Hospital

Active, not recruiting

Serplulimab for Patients With Non-small Cell Lung Cancer (NSCLC) With TPS ≥ 50%: a Prospective, Single-center, Single-arm Phase 2 Study. (NSCLC)

Non-small Cell Lung Cancer | PDL1 Gene Mutation

China
Instituto Nacional de Cancerologia de Mexico

Completed

MK-3475 in Combination With Docetaxel vs Docetaxel Alone in Non-Small Cell Lung Cancer Patients

Carcinoma, Non-Small-Cell Lung

Mexico
Viriom

Unknown

Phase Ib Study of Safety, Tolerability and Pharmacokinetics of Elpida Once Weekly in Healthy Volunteers

HIV Infections

Thailand
University of Turin, Italy

Recruiting

UNITO-001- Study in HRR/PDL1 Positive MPM/NSCLC (UNITO-001)

Lung Cancer | Mesothelioma

Italy
Merck Sharp & Dohme LLC

Completed

Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001)

Neoplasms
Merck Sharp & Dohme LLC

Active, not recruiting

Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)

Neoplasms

Poland, United States, Australia, Canada, China, France, Greece, Israel, Japan, Korea, Republic of, South Africa, Spain
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)

Hodgkin's Lymphoma | Primary Mediastinal Large B-cell Lymphoma (PMBCL)

Canada, United States, Brazil, Czechia, France, Italy, Poland, Russian Federation, South Africa, Turkey, Ukraine
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy Study of Pembrolizumab (MK-3475) in Chinese Participants With Locally Advanced or Metastatic Melanoma (MK-3475-151/KEYNOTE-151)

Melanoma
Merck Sharp & Dohme LLC

Completed

A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013)

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Multiple Myeloma | Hodgkin Lymphoma | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Primary Mediastinal B-Cell Lymphoma
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012)

Cancer | Solid Tumor
Merck Sharp & Dohme LLC

Terminated

A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023)

Multiple Myeloma
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Bintrafusp Alfa Before Surgery for the Treatment of Untreated Resectable Non-small Cell Lung Cancer

Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Resectable Lung Non-Small Cell Carcinoma | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage... and other conditions

United States
Glenn Jaffe

Completed

Pilot Study of a Fluocinolone Acetonide Intravitreal Insert (FA-i) to Treat Intermediate-, Posterior-, or Panuveitis (Iluvien)

Uveitis Affecting the Posterior Segment

United States
Merck Sharp & Dohme LLC

Recruiting

MK-2870 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)

Non-small Cell Lung Cancer | Solid Tumors | Programmed Cell Death-1 (PD1, PD-1) | Programmed Cell Death 1 Ligand 1(PDL1, PD-L1) | Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)

Japan
Merck Sharp & Dohme LLC

Recruiting

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

Solid Tumors | Hematologic Malignancies

United States, Poland, Brazil, Ukraine, Argentina, Australia, Austria, Belgium, Canada, Chile, China, Colombia, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Israel, Italy, Japan, Korea, Republic... and more
Merck Sharp & Dohme LLC

Completed

Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)

Non-small Cell Lung Cancer

China, Taiwan, Japan, Korea, Republic of, United States, Australia, Brazil, Canada, France, Germany, Hong Kong, Israel, Italy, Mexico, Spain, Sweden, United Kingdom
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

Breast Cancer

Japan, Poland, United States, Australia, Belgium, Brazil, Canada, China, Colombia, Costa Rica, France, Germany, Hungary, Ireland, Israel, Korea, Republic of, New Zealand, Portugal, Puerto Rico, Russian Federation, Spain, Taiwan, Ukr... and more
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)

Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC

Completed

A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)

Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC

Terminated

Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)

Multiple Myeloma
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) in Participants With Advanced Non-small Cell Lung Cancer (MK-3475-025/KEYNOTE-025)

Non-small Cell Lung Cancer
Sun Yat-sen University

Recruiting

Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma | Bevacizumab | Anti-PD1/PDL1 Antibody

China
University of Arizona
National Cancer Institute (NCI)

Recruiting

SUV PDL1/PD1 in Sun Damaged & Sun Protected Human Skin of Participants

Other Skin Changes Due to Chronic Exposure to Nonionizing Radiation

United States
University of Michigan Rogel Cancer Center

Completed

Abraxane With Anti-PD1/PDL1 in Patients With Advanced Urothelial Cancer (ABLE)

Urothelial Carcinoma

United States
Gustave Roussy, Cancer Campus, Grand Paris

Unknown

Atezolizumab With Stereotactic Ablative Radiotherapy in Patients With Metastatic Tumours (SABR-PDL1)

Patients With Metastatic Tumours (Colorectal Cancer, Non-small Lung Cancer, Renal Cell Carcinoma or Sarcoma )

France
Merck Sharp & Dohme LLC

Recruiting

Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)

Bladder Cancer

Canada, France, Italy, Netherlands, Turkey, Brazil, Spain, United States, Finland, Puerto Rico, Singapore
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087)

Hodgkin Lymphoma
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)

Triple Negative Breast Neoplasms

Brazil, Canada, United States, United Kingdom, Taiwan, Australia, Colombia, France, Germany, Ireland, Israel, Italy, Japan, Korea, Republic of, Poland, Portugal, Russian Federation, Singapore, Spain, Sweden, Turkey
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-041/KEYNOTE-041)

Melanoma
University Hospital, Brest

Recruiting

Prognostic Value of Combined Approach Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT Radiomic Analysis in Advanced Non-small-cell Lung Cancer PDL1 ≥ 50% Treated With Pembrolizumab (PEMBROMIC) (PEMBROMIC)

Lung Cancer Stage III | Lung Cancer Stage IV

France
Radiopharm Theranostics, Ltd

Recruiting

177Lu-anti-PD-L1 sdAb in Metastatic Non-small Cell Lung Cancer

Non Small Cell Lung Cancer | PDL1 Gene Mutation

Australia
Merck Sharp & Dohme LLC

Terminated

Study of MK-1248 With and Without Pembrolizumab (MK-3475) for Participants With Advanced Solid Tumors (MK-1248-001)

Advanced Solid Tumor
University of Alabama at Birmingham

Not yet recruiting

DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC

Non-Small Cell Lung Cancer | PDL1 Negative Non-Small Cell Lung Cancer (NSCLC)

United States

Search clinical trials for: EUS-FNB, PDL1, MMR

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saudi Arabia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations